Traxlink PB 550 Tablet contains Tranexamic Acid 500 mg (Sustained Release) and Pine Bark Extract 50 mg, a specialized combination formulated to help manage excessive bleeding while providing antioxidant and vascular support. The sustained-release formulation helps maintain therapeutic levels of Tranexamic Acid over an extended period, while Pine Bark Extract contributes beneficial bioactive compounds that support vascular integrity. The medicine is prescribed under medical supervision for conditions associated with abnormal bleeding.
Tranexamic Acid works by inhibiting the conversion of plasminogen to plasmin, thereby reducing fibrinolysis and helping stabilize blood clots to control excessive bleeding. The sustained-release technology provides prolonged therapeutic activity. Pine Bark Extract is rich in naturally occurring procyanidins and antioxidants that help support blood vessel health, improve microcirculation, and protect tissues from oxidative stress. Together, these ingredients offer a comprehensive approach to bleeding management and vascular support.
The tablet is commonly prescribed for heavy menstrual bleeding (menorrhagia), bleeding associated with gynecological conditions, postoperative bleeding, and other situations requiring antifibrinolytic therapy as advised by a healthcare professional. Appropriate use may help reduce blood loss, improve patient comfort, and support overall treatment outcomes. The dosage and duration of therapy should always be determined by the treating physician according to the patient's clinical condition.
With the increasing prevalence of gynecological disorders and the growing demand for advanced hemostatic therapies, Traxlink PB 550 Tablet maintains strong demand in the gynecology and hematology segments. Its innovative sustained-release formulation, physician acceptance, and broad clinical utility contribute to sustained market potential. The product offers valuable business opportunities and long-term growth prospects for retailers and distributors operating within the pharmaceutical hemostatic sector.